1-18 of 18
Richard B. Lock
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C095: The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia

Free
Richard B Lock, Kathryn Evans, Sophia Gawan-Taylor, Ben Watts, Timothy Stearns, Eric J Earley, Emily L Jocoy, Carol J Bult, Beverly A Teicher, Gerard M McGeehan, Malcolm A Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C095.
https://doi.org/10.1158/1535-7163.TARG-23-C095
Published: 01 December 2023
View articletitled, Abstract C095: The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia
Journal Articles

Abstract B134: Targeting Philadelphia chromosome-like acute lymphoblastic leukemia with a novel CRLF2 antibody fragment-drug conjugate

Free
Richard B Lock, Sara M.A. Mohamed, Peter Schofield, Karl-Heinz Friedrich, Daniel Christ, Maria Kavallaris, Narges Bayat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B134.
https://doi.org/10.1158/1535-7163.TARG-23-B134
Published: 01 December 2023
View articletitled, Abstract B134: Targeting Philadelphia chromosome-like acute lymphoblastic leukemia with a novel CRLF2 antibody fragment-drug conjugate
Journal Articles

Abstract P143: Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia

Free
Patrick Connerty, Ernest Moles, Charles deBock, Nisitha Jayatilleke, Jenny L. Smith, Soheil Meshinchi, Chelsea Mayoh, Maria Kavallaris, Richard B. Lock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P143.
https://doi.org/10.1158/1535-7163.TARG-21-P143
Published: 01 December 2021
View articletitled, Abstract P143: Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia
Journal Articles

PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis

Free
James T. Lim, Neha Singh, Libia A. Leuvano, Valerie S. Calvert, Emanuel F. Petricoin, David T. Teachey, Richard B. Lock, Megha Padi, Andrew S. Kraft, Sathish K.R. Padi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (9): 1809–1821.
https://doi.org/10.1158/1535-7163.MCT-20-0160
Published: 02 September 2020
View articletitled, PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis
Open the PDF for PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis in another window
Includes: Supplementary data
Journal Articles

Abstract C004: The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia

Free
Richard B Lock, Kathryn Evans, Connor D Jones, Narimanne El-Zein, Stephen W Erickson, Sarah Beaussant-Cohen, E. Lynne Kelley, Beverly A Teicher, Malcolm A Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C004.
https://doi.org/10.1158/1535-7163.TARG-19-C004
Published: 01 December 2019
View articletitled, Abstract C004: The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia
Journal Articles

Abstract A123: Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression

Free
Richard B Lock, Cara E Toscan, Duohui Jing, Chelsea Mayoh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A123.
https://doi.org/10.1158/1535-7163.TARG-19-A123
Published: 01 December 2019
View articletitled, Abstract A123: Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression
Journal Articles

Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study

Free
Richard B. Lock, Kathryn Evans, Raymond Yung, Tara Pritchard, Beverly A. Teicher, JianXin Duan, Yuelong Guo, Stephen W. Erickson, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B16.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B16
Published: 01 January 2018
View articletitled, Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study
Journal Articles

Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Free
Beverly A. Teicher, Richard B. Lock, Jerry M. Collins, Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Raushan T. Kurmasheva, Xiao-Nan Li, Stephen W. Erickson, Yuelong Guo, Kathryn Evans, Lin Qi, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B12.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B12
Published: 01 January 2018
View articletitled, Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)
Journal Articles

Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

Free
Kateryna Krytska, Kathryn Evans, Tara Pritchard, Matthew Tsang, Raymond Yung, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Erkan Baloglu, Yosef Landesman, Kyle A. Jensen, William Senapedis, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B14.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B14
Published: 01 January 2018
View articletitled, Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602
Journal Articles

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Free
Santi Suryani, Lauryn S. Bracken, Richard C. Harvey, Keith C.S. Sia, Hernan Carol, I-Ming Chen, Kathryn Evans, Philipp A. Dietrich, Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-14-0647
Published: 09 February 2015
View articletitled, Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia
Open the PDF for Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Induction of Vascular Endothelial Growth Factor Secretion by Childhood Acute Lymphoblastic Leukemia Cells via the FLT-3 Signaling Pathway

Free
Ana Markovic, Karen L. MacKenzie, Richard B. Lock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 183–193.
https://doi.org/10.1158/1535-7163.MCT-11-0503
Published: 09 January 2012
View articletitled, Induction of Vascular Endothelial Growth Factor Secretion by Childhood Acute Lymphoblastic Leukemia Cells via the FLT-3 Signaling Pathway
Open the PDF for Induction of Vascular Endothelial Growth Factor Secretion by Childhood Acute Lymphoblastic Leukemia Cells via the FLT-3 Signaling Pathway in another window
Includes: Supplementary data
Journal Articles

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

Free
C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard B. Lock, Richard Gorlick, E. Anders Kolb, Denise Alexander, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Jianrong Wu, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C106.
https://doi.org/10.1158/1535-7163.TARG-11-C106
Published: 12 November 2011
View articletitled, Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).
Journal Articles

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Free
Peter J. Houghton, John M. Maris, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Kathleen R. Whiteman, Malcolm Anders Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C105.
https://doi.org/10.1158/1535-7163.TARG-11-C105
Published: 12 November 2011
View articletitled, Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.
Journal Articles

Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Free
Malcolm A. Smith, Min H. Kang, Christopher Patrick Reynolds, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, John M. Maris, Stephen T. Keir, Catherine A. Billups, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C103.
https://doi.org/10.1158/1535-7163.TARG-11-C103
Published: 12 November 2011
View articletitled, Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.
Journal Articles

Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Free
Richard B. Lock, Hernan Carol, Barbara Szymanska, Ingrid Boehm, Kathryn Evans, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C107.
https://doi.org/10.1158/1535-7163.TARG-11-C107
Published: 12 November 2011
View articletitled, Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Journal Articles

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Free
Peter J. Houghton, Christopher L. Morton, Richard Gorlick, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy W. Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 101–112.
https://doi.org/10.1158/1535-7163.MCT-09-0952
Published: 12 January 2010
View articletitled, Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Open the PDF for Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Free
Peter J. Houghton, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, E. Anders Kolb, Richard Gorlick, Min Kang, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C57.
https://doi.org/10.1158/1535-7163.TARG-09-C57
Published: 10 December 2009
View articletitled, Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase
Journal Articles

Abstract A135: Evaluation of CPX‐351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models

Free
Lawrence Mayer, Hernan Carol, Christopher L. Morton, Troy Harasym, Malcolm A. Smith, Richard B. Lock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A135.
https://doi.org/10.1158/1535-7163.TARG-09-A135
Published: 10 December 2009
View articletitled, Abstract A135: Evaluation of CPX‐351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models